Dostarlimab for early-stage MMR deficient endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have stage 1, grade 1 or 2 endometrioid endometrial cancer that is MMR deficient (a specific type of cancer cell).
- You want to keep your uterus or are not a candidate for hysterectomy.
- You are generally well enough to be up and about (ECOG score 0-2).
- You have adequate organ function (kidneys, liver, blood counts) and no signs of cancer spread outside the uterus.
- You are not pregnant and willing to use effective contraception if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
This study is testing the safety of an immunotherapy drug called dostarlimab (Jemperli) in patients with a type of endometrial cancer that has returned, spread, or not improved after previous chemotherapy. The drug works by helping your immune system fight the cancer, and the study is specifically for patients whose tumors have certain genetic features (dMMR or MSI-H).
This trial tests whether giving a drug called dostarlimab (an immunotherapy that boosts your immune system to fight cancer) before and after surgery can help treat advanced endometrial cancer. It is for people with stage 3 or 4 endometrial cancer who haven't had treatment yet and may be eligible if their tumor has a specific marker called mismatch repair deficiency.
This trial tests a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) in people with advanced or recurrent endometrial cancer. The goal is to see if the drug is safe and effective for this type of cancer.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
Hear when a new Endometrial Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.